Factor V Leiden is Associated with Higher Risk of Deep Venous Thrombosis of Large Blood Vessels

Overview

Journal Croat Med J

Specialty General Medicine

Date 2006 Jun 8

PMID 16758522

Citations 14

Authors

Todor Arsov

Daniela Miladinova

Mirko Spiroski

Affiliations

Soon will be listed here.

Abstract

Aim: To determine the prevalence of factor V Leiden mutation in patients with different presentation of venous thromboembolic disease and healthy individuals in the Republic of Macedonia.

Methods: The retrospective case control study involved 190 patients with venous thromboembolic disease and 200 healthy individuals, who were screened for the presence of factor V Leiden mutation, using a polymerase chain reaction-restriction fragment length polymorphism method. The prevalence of factor V Leiden was analyzed according to the localization of thrombosis, presence of risk factors, and family history of thrombosis. The odds of deep venous thrombosis were calculated with respect to the presence of factor V Leiden mutation.

Results: The prevalence of factor V Leiden mutation among patients with venous thromboembolic disease was 21.1%, compared with 5.5% in the healthy individuals. Factor V Leiden positive patients had the first episode of deep venous thrombosis at a younger age, and the prevalence of the mutation was the highest among patients with a positive family history of thrombosis (33.9%, P=0.003) and in patients with deep venous thrombosis affecting a large blood vessel (37.7%, P=0.001). The prevalence of factor V Leiden mutation was lower in patients with calf deep venous thrombosis and primary thromboembolism (13.3% and 13.1%, respectively; P>0.05). The odds ratio for iliofemoral or femoral deep venous thrombosis in factor V Leiden carriers was 10.4 (95% confidence interval, 4.7-23.1).

Conclusion: The prevalence of factor V Leiden mutation was high in patients with venous thromboembolic disease and healthy individuals in the Republic of Macedonia. Factor V Leiden carriers have the highest odds of developing deep venous thrombosis affecting a large venous blood vessel.

Citing Articles

Clinical characteristics and thrombophilia associated gene variants in Egyptians with unprovoked venous thromboembolism: three centers experience.

Efat A, Shoeib S, Abdelmonem A, Elamawy M, Eleleimy H, Ibrahem R Mol Biol Rep. 2024; 51(1):1013.

PMID: 39325233 DOI: 10.1007/s11033-024-09909-4.

Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis.

Alnor A, Gils C, Vinholt P Ann Hematol. 2024; 103(10):4285-4294.

PMID: 39167180 PMC: 11512919. DOI: 10.1007/s00277-024-05926-2.

Large-scale screening for factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek population.

Raptopoulou A, Michou V, Mourtzi N, Papageorgiou E, Voyiatzaki C, Tsilivakos V Health Sci Rep. 2022; 5(4):e457.

PMID: 35844826 PMC: 9284178. DOI: 10.1002/hsr2.457.

[Loss of visual acuity after vaccination?].

Kesper C, Kegel T, Viestenz A, Viestenz A Ophthalmologie. 2021; 119(8):860-863.

PMID: 34878595 PMC: 8652098. DOI: 10.1007/s00347-021-01539-6.

Deep Vein Thrombosis and the Neurosurgical Patient.

Rethinasamy R, Alias A, Kandasamy R, Raffiq A, Looi M, Hillda T Malays J Med Sci. 2019; 26(5):139-147.

PMID: 31728126 PMC: 6839661. DOI: 10.21315/mjms2019.26.5.13.

References

Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa M . Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000; 343(14):1015-8. DOI: 10.1056/NEJM200010053431405. View

Bjorgell O, Nilsson P, Nilsson J, Svensson P . Location and extent of deep vein thrombosis in patients with and without FV:R 506Q mutation. Thromb Haemost. 2000; 83(5):648-51. View

Coen D, Zadro R, Honovic L, Banfic L, Stavljenic Rukavina A . Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat Med J. 2001; 42(4):488-92. View

Boyanovsky B, Russeva M, Ganev V, Penev M, Baleva M, Russev M . Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis. Blood Coagul Fibrinolysis. 2001; 12(8):639-42. DOI: 10.1097/00001721-200112000-00004. View

Poncz M, Solowiejczyk D, Harpel B, Mory Y, Schwartz E, Surrey S . Construction of human gene libraries from small amounts of peripheral blood: analysis of beta-like globin genes. Hemoglobin. 1982; 6(1):27-36. DOI: 10.3109/03630268208996930. View

. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 1990; 263(20):2753-9. DOI: 10.1001/jama.1990.03440200057023. View

Dahlback B, Carlsson M, Svensson P . Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993; 90(3):1004-8. PMC: 45799. DOI: 10.1073/pnas.90.3.1004. View

Svensson P, Dahlback B . Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994; 330(8):517-22. DOI: 10.1056/NEJM199402243300801. View

Bertina R, Koeleman B, Koster T, Rosendaal F, Dirven R, de Ronde H . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-7. DOI: 10.1038/369064a0. View

10.

Voorberg J, Roelse J, Koopman R, Buller H, Berends F, Ten Cate J . Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994; 343(8912):1535-6. DOI: 10.1016/s0140-6736(94)92939-4. View

11.

Dahlback B . Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood. 1995; 85(3):607-14. View

12.

Ridker P, Hennekens C, Lindpaintner K, Stampfer M, Eisenberg P, Miletich J . Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332(14):912-7. DOI: 10.1056/NEJM199504063321403. View

13.

Rosendaal F, Koster T, Vandenbroucke J, Reitsma P . High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995; 85(6):1504-8. View

14.

Rees D, Cox M, Clegg J . World distribution of factor V Leiden. Lancet. 1995; 346(8983):1133-4. DOI: 10.1016/s0140-6736(95)91803-5. View

15.

Dahlback B . New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost. 1995; 74(1):139-48. View

16.

Desmarais S, de Moerloose P, Reber G, Minazio P, Perrier A, Bounameaux H . Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet. 1996; 347(9012):1374-5. DOI: 10.1016/s0140-6736(96)91013-2. View

17.

Rees D . The population genetics of factor V Leiden (Arg506Gln). Br J Haematol. 1996; 95(4):579-86. DOI: 10.1046/j.1365-2141.1996.d01-1954.x. View

18.

Simioni P, Prandoni P, Lensing A, Scudeller A, Sardella C, Prins M . The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997; 336(6):399-403. DOI: 10.1056/NEJM199702063360602. View

19.

Pepe G, Rickards O, Vanegas O, Brunelli T, Gori A, Giusti B . Prevalence of factor V Leiden mutation in non-European populations. Thromb Haemost. 1997; 77(2):329-31. View

20.

Ridker P, Miletich J, Hennekens C, Buring J . Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277(16):1305-7. View